Published • loading... • Updated
Evommune scraps eczema drug after trial miss, shares plunge
The trial enrolled 121 adults and failed to meet primary or secondary goals, while Evommune said it will keep developing EVO756 for migraine prevention.
Summary by WTVB
4 Articles
4 Articles
Evommune scraps eczema drug after trial miss, shares plunge - Regional Media News
Sept 8 (Reuters) - Evommune said on Tuesday it will not advance its experimental skin disease drug after it failed to meet the main goal in a mid-stage trial, sending its shares down 24% in aftermarket trading. Here are some details • The company said [...]
Evommune scraps eczema drug after trial miss, shares plunge
Sept 8 (Reuters) - Evommune said on Tuesday it will not advance its experimental skin disease drug after it failed to meet the main goal in a mid-stage trial, sending its shares down 24% in aftermarket trading. Here are some details • The company sai...
Coverage Details
Total News Sources4
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
